This research trial studies whole exome sequencing in finding causative variants in germline deoxyribonucleic acid (DNA) samples from patients with peripheral neuropathy receiving chemotherapy for breast cancer. Studying samples of germline DNA in the laboratory from patients with peripheral neuropathy receiving paclitaxel for breast cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to peripheral neuropathy.
European American patients with DNA available and designated case or control
African American patients with DNA available and designated case or control status
Patients who developed grade 2-4 for African American (AA) and grade 3-4 for European American (EA) peripheral neuropathy during their treatment with paclitaxel and who did not develop peripheral neuropathy following a full course of treatment with paclitaxel
None
Patients with breast cancer enrolled on E5103 with or without peripheral neuropathy.
Case-control
Retrospective
Laboratory Biomarker Analysis
Other interventionCorrelative studies
Identification of rare coding variants of large effect that predict the risk of peripheral neuropathy
Assess by Burden analysis.
Click on the lead sponsor to view all of their trials.
